Navigation Links
Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media

NEW YORK, Nov. 12 /PRNewswire/ -- Euro RSCG Life today presented findings and insights from proprietary research and analysis of 1,700-plus social media users at the United States Food and Drug Administration hearing "Promotion of Food and Drug Administration-regulated medical products using the Internet and social media tools."

The research, first consisting of a survey of 1,228 social media users, analyzed thousands of verbatims and other conversations across blogs, Twitter and online forums. A follow-up survey of more than 520 social media users was also conducted, with a focus on health-related information.

"This research further underscores the value of online and social media and confirms it is not just a fad for a select group of consumers," said Donna Murphy, worldwide managing partner of Euro RSCG Life Worldwide. "Social media has instead become more relevant in consumer communications, not only supporting offline social dialogues but also allowing people to research and seek out proper health care. This FDA hearing has arrived at a critical juncture of social media's upward trajectory and health care's emergence as a major political issue."

The survey found that consumers use much more electronic communication than 10, five and even one year ago, and that digital socialization has become a part of their daily lives. Only 12 percent of those surveyed thought social media was just a fad, and one-third believed it would become an even greater part of their lives in years to come.

Additional findings from this research include:

  • Nearly nine out of 10 surveyed said they consider the Internet a reputable source of health-related information and would use it as a resource.
  • More than 80 percent had previously turned to the Internet for information about a particular treatment, and 44 percent stated they would also turn to social media for similar information.
  • Safety information is a significant determining factor for consumers: Twice as many respondents said they would click a link that promised to provide additional safety information than one that did not make such an offer.
  • Of those who had previously researched treatment information online, 28 percent are comfortable with the level of safety information currently provided.
  • However, more than a third of those surveyed would like to see more safety information made available, if possible.
  • Nearly one-third of those surveyed take the information they find online to initiate a conversation with their doctor, while another third use that information to develop their own health plan.
  • Even when it was not the direct catalyst for doctor-patient dialogue, two-thirds of all surveyed stated they found social media a helpful source of health information when they eventually spoke to their physician on the subject.

"Until the FDA's official guidance is issued based on this week's hearing and information exchange, the pharma industry, and those of us who communicate on its behalf, will continue to monitor this subject very closely," said Doug Burcin, worldwide managing partner of Euro RSCG Life Worldwide. "These statistics suggest that once this guidance is in place, there is an audience ready to use social media to help them make more informed decisions about their health."

For more information, please visit

About Euro RSCG Life

Euro RSCG Life aligns the company's 60 health-focused agencies in 50 countries. It creates a single network with over 2,000 employees offering clients comprehensive communications disciplines, including advertising, public relations, event promotion, medical education, digital marketing, direct to patient and consulting services. The network's client roster includes GlaxoSmithKline, Novartis, Pfizer, sanofi-aventis, and Schering-Plough. Euro RSCG Life is part of Euro RSCG Worldwide, a leading global marketing communications agency, and the largest unit of Havas, the world's fourth-largest communications group (Euronext Paris SA: HAV.Pa).

About Euro RSCG Worldwide

Euro RSCG Worldwide, the parent company of Euro RSCG Worldwide PR, is a leading integrated marketing communications agency and 2006 Global Agency of the Year in Advertising Age and Campaign. Euro RSCG is made up of 233 offices in 75 countries throughout Europe, North America, Latin America, Asia-Pacific and the Middle East and provides advertising, marketing, corporate communications and interactive solutions to global, regional and local clients. The agency's client roster includes Air France, BNP Paribas, Charles Schwab, Citigroup, Danone Group, Heineken USA, IBM, Jaguar, Kraft Foods, Lacoste, L'Oreal, Pernod Ricard, PSA Peugeot Citroen, Reckitt Benckiser, sanofi-aventis and Schering-Plough. Headquartered in New York, Euro RSCG Worldwide is the largest unit of Havas, a world leader in communications (Euronext: HAV.PA) (Paris: HAV.PA).

    Jamie Bernheim
    Euro RSCG Worldwide PR

SOURCE Euro RSCG Worldwide

SOURCE Euro RSCG Worldwide
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... ... exchange technology and teleradiology services, has added Chris Hafey and Claude Hooton to ... at the Radiological Society of North America (RSNA) 2015 Annual Meeting and continues ...
(Date:11/28/2015)... ... 2015 , ... Pixel Film Studios is back again with ProPanel: Pulse ... are endless. Users have full control over angle of view, speed method, start point, ... sure to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape ...
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
Breaking Medicine News(10 mins):